Indian pharma industry capable of discovering new drugs: Dilip Shanghvi

Industry should gear up to strengthen the core areas such as clinical development and research capabilities, he adds

Dilip Shanghvi
Press Trust of India Hyderabad
Last Updated : Aug 29 2015 | 7:55 PM IST
Indian pharma industry is capable of discovering at least a couple of new drugs in the next 10 years, Sun Pharmaceutical Industries founder and managing director Dilip Shanghvi said today.

He, however, cautioned that the industry should gear up to strengthen the core areas such as clinical development and research capabilities.

"India has enormous opportunity to discover drugs but there are a few areas where we need to strengthen our capabilities - especially in the area of biology and clinical development.

Also Read

"I am sure within next 10 years, we will have new drugs from Indian firms as well," Shanghvi said at the symposium 'DRILS Synergy 2015' organised by the Dr Reddy's Institute of Life Sciences (DRILS).

He said Indian Pharma companies including Sun Pharma are setting up labs abroad due to lack of expertise in India in the areas necessary.

Later speaking to reporters, GV Prasad - Dr Reddy's Laboratories co-chairman and chief executive officer said DRILS, which was incorporated in 2004, is working with over 20 pharma companies from India as well as abroad in their research projects.

DRILS will step up its focus on collaboration with start-ups besides big corporates in research, Prasad said.

Akella Venkateswarlu, Founder-Director of DRILS, said the institute is ready to offer solution-focussed research to industry in life sciences, drug discovery and product development.

According to him, DRILS focuses mainly focusing on the areas of metabolic disorders, immunology and zebra fish biology.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 29 2015 | 7:42 PM IST

Next Story